*By Michael Teich* [Twelve percent](https://migraineresearchfoundation.org/about-migraine/migraine-facts/) of the U.S. population may suffer from chronic migraines, but many Americans don't appreciate the impact, said president of Lilly Bio-Medicines Christi Shaw. "These patients need to be treated seriously. This is a neurological disorder," Shaw said Friday in an interview on Cheddar. Eli Lilly ($LLY) just received clearance from the FDA for its latest drug, and it could change the lives of the 39 million Americans suffering from migraines, according to Shaw. The treatment, Emgality, is a monthly, self-administered injection that will help patients cut the frequency of their migraines in half, she said. Shaw said that many Americans conflate headaches and migraines, and so they often dismiss their pain. They key difference is that the symptoms of a migraine disrupt one's ability to function optimally through the day. That doesn't happen with a more commonplace headache. And a stigma contributes to the glaring statistic that only about 10 percent of those suffering from migraines take prescription drugs for prevention, Shaw said. Emgality comes with a serious price tag: $6,900 a year, or $575 a month. But Eli Lilly is offering commercially insured patients up to 12 months of the drug for free. It's among the latest efforts from the industry to offer consumers some relief from surging drug costs. Competitors Amgen ($AMGN) and Teva ($TEVA) have already unveiled new migraine treatment drugs. For full interview [click here](https://cheddar.com/videos/eli-lilly-gets-fda-approval-for-new-migraine-treatment).

Share:
More In Science
The U.S. Faces a Massive Plastic Waste Problem — What is Congress Doing About It?
The U.S. has a million-ton problem: each year, hundreds of pounds of plastic waste are produced per person, and that leads to close to 2 million tons of that waste leaking into the environment. Eight million tons end up in the ocean, where it hinders marine life, damages ecosystems, and impacts industry. But in recent years, Congress has introduced measures including the Save our Seas act to try to mitigate the issue and turn our plastic problem around. Sen. Chris Murphy (D-CT) joins Cheddar Climate to discuss why the U.S. is the top global polluter of plastic, what Congress is doing to try to fix the issue, and more.
The Politics of a COVID-19 Vaccine Mandate
While the World Health Organization strongly advises against a COVID-19 vaccine mandate, national and local governments are moving to make inoculations compulsory. Cheddar News speaks with Dr. Joel Zinberg of the Competitive Enterprise Institute on the issue.
The Challenge of Plastic Recycling
Cheddar breaks down the challenges of plastic recycling and what one company is doing to help offset the negative environmental impact of single-use plastics.
Why Commercial Planes Are Shrinking
Earlier this year, JetBlue flew its inaugural flight into the United Kingdom. It was a game changer — not only did the airline enter the transatlantic market, but the plane that completed the flight was a single-aisle jet. For decades, flying the distance was synonymous with jumbo jets, but today narrow-body aircraft are now proving they are up for the task — and maybe even the best option. In this episode, Cheddar examines why airlines are betting on narrow-body aircraft.
Design Disasters Of The Human Body
Humans are scientifically the most successful species in the history of planet earth. And for this we can thank our opposable thumbs, proportionally large brains, and our upright posture. But for all our anatomical wonders, we still have some pretty major flaws.
Load More